<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580904</url>
  </required_header>
  <id_info>
    <org_study_id>UEParaiba</org_study_id>
    <nct_id>NCT01580904</nct_id>
  </id_info>
  <brief_title>Impact of Pharmaceutical Care in Diabetics Patients</brief_title>
  <acronym>IPCD</acronym>
  <official_title>Popular Pharmacy of Brazil: Impact of Pharmaceutical Care in Diabetics Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual da Paraiba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade Federal do Rio Grande do Norte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Estadual da Paraiba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The monitoring of diabetics by the pharmacist may contribute to the effectiveness of drug
      treatment and to improve their quality of life. This study will measure the impact of
      pharmacotherapeutic follow-up in diabetic patients. This will be a clinical trial, single
      blind, controlled, randomized, conducted in two units of pharmacies in Brazil. Only in the
      intervention group will be held the pharmacotherapeutic follow using a methodology called the
      practice of pharmaceutical care, which identifies and resolves problems related to drugs. The
      primary outcome is glycated hemoglobin, and secondary outcomes are baseline glucose, total
      cholesterol and its fractions (for example LDL), all these measures will be made in the
      intervention group and control group. Patients will be followed for 24 weeks, and the
      outcomes will be assessed up to 24 weeks. There will be a confidence interval of 95% and a
      significance of p &lt;0.05, and will use the Student t test, chi-square analysis of variance
      (ANOVA) and others if necessary. Expects good results and serve as a model for other
      researchers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated Hemoglobin</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>average glycated hemoglobin over 24 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Glycemia</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>average fasting glycemia over 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>average total cholesterol over 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>average LDL cholesterol over 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not be followed by the pharmacist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.
Intervention: Pharmaceutical Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intervention: Pharmaceutical Care</intervention_name>
    <description>Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion criteria:

          -  patients aged 30 years,

          -  diagnosed with type 2 diabetes,

          -  to make use of oral antidiabetic agents with or without insulin

        Exclusion Criteria:

        those who had infectious diseases during the research

          -  missed three consecutive interviews,

          -  suspended the hypoglycemic drug and medical order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivonete A. Doutorado</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal do Rio Grande do Norte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Estadual da Paraíba</name>
      <address>
        <city>João Pessoa</city>
        <state>Paraíba</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.pharmacypractice.org/</url>
    <description>A journal that has a lot of research on this topic</description>
  </link>
  <link>
    <url>http://www.pec-journal.com/article/S0738-3991(07)00228-5/abstract</url>
    <description>An interesting article on this topic</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387287/</url>
    <description>An interesting article on this topic</description>
  </link>
  <reference>
    <citation>Mitchell B, Armour C, Lee M, Song YJ, Stewart K, Peterson G, Hughes J, Smith L, Krass I. Diabetes Medication Assistance Service: the pharmacist's role in supporting patient self-management of type 2 diabetes (T2DM) in Australia. Patient Educ Couns. 2011 Jun;83(3):288-94. doi: 10.1016/j.pec.2011.04.027. Epub 2011 May 26.</citation>
    <PMID>21616627</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <results_first_submitted>March 11, 2016</results_first_submitted>
  <results_first_submitted_qc>December 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2017</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual da Paraiba</investigator_affiliation>
    <investigator_full_name>Patrícia Trindade Costa Paulo</investigator_full_name>
    <investigator_title>Impact of Pharmaceutical Care in Diabetics Patients: Clinical Trial Randomized</investigator_title>
  </responsible_party>
  <keyword>Pharmaceutical Care</keyword>
  <keyword>Diabetics patients</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From September 2009 to December 2011.Medical clinic</recruitment_details>
      <pre_assignment_details>The exclusion criteria were (i) to have an infectious disease during the study, (ii) to miss three consecutive appointments, (iii) to stop the use of the hypoglycemic drugs by order of the doctor, and (iv) to deny the acceptance of the term of free and informed consent (TFIC).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group</title>
          <description>Patients will be followed by the pharmacist.
Intervention: Pharmaceutical Care : Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Patients will not be followed by the pharmacist.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group</title>
          <description>Patients will be followed by the pharmacist.
Intervention: Pharmaceutical Care : Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Patients will not be followed by the pharmacist.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycated Hemoglobin</title>
        <description>average glycated hemoglobin over 24 weeks</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Data are glycated hemoglobin means of all patients per group.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will not be followed by the pharmacist.</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Patients will be followed by the pharmacist.
Intervention: Pharmaceutical Care: Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
          </group>
        </group_list>
        <measure>
          <title>Glycated Hemoglobin</title>
          <description>average glycated hemoglobin over 24 weeks</description>
          <population>Data are glycated hemoglobin means of all patients per group.</population>
          <units>percent (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.5"/>
                    <measurement group_id="O2" value="7.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Glycemia</title>
        <description>average fasting glycemia over 24 weeks</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will not be followed by the pharmacist.</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.
Intervention: Pharmaceutical Care
Intervention: Pharmaceutical Care: Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glycemia</title>
          <description>average fasting glycemia over 24 weeks</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.7" spread="43.1"/>
                    <measurement group_id="O2" value="159.3" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <description>average total cholesterol over 24 weeks</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will not be followed by the pharmacist.</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.
Intervention: Pharmaceutical Care
Intervention: Pharmaceutical Care: Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>average total cholesterol over 24 weeks</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.9" spread="42.8"/>
                    <measurement group_id="O2" value="191.1" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL Cholesterol</title>
        <description>average LDL cholesterol over 24 weeks</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will not be followed by the pharmacist.</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.
Intervention: Pharmaceutical Care
Intervention: Pharmaceutical Care: Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Cholesterol</title>
          <description>average LDL cholesterol over 24 weeks</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.0" spread="33.0"/>
                    <measurement group_id="O2" value="110.8" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Patients will not be followed by the pharmacist.</description>
        </group>
        <group group_id="E2">
          <title>Intervention Group</title>
          <description>Patients will be followed by the pharmacist.
Intervention: Pharmaceutical Care: Patients will be followed by the pharmacist by the Pharmaceutical Care Practice</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Queasiness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Impacto da Atenção Farmacêutica em pacientes diabéticos (IPCD)</name_or_title>
      <organization>Universidade Estadual da Paraíba</organization>
      <phone>558387010977</phone>
      <email>patriciatrindad@yahoo.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

